Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Budgets fail for reasons like over-optimism and failure to monitor; address these with realism, alerts, and consistent evaluation.
7,488 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Bitcoin briefly pushed into the mid-$60,000s before pulling back, while a top analyst cautions that the bounce may no...
PayPal has faced a long stretch of underperformance, leaving investors wondering if the stock is a true bargain or a ...
Astera Labs sits at a pivotal point in the data center supply chain. This article breaks down why the stock could ris...
Retail investors gain broader access to funding startups before IPOs, but the risks and illiquidity demand discipline...
XRP and ETH traders are driving a surge in fear of missing out, lifting sentiment to multi-week highs even as prices ...
When a crypto exchange missteps, the ripple is felt beyond traders. This article explores why south korean lawmakers ...
Hyped up rare-earth plays attract attention, but many stumble before they mine. This guide breaks down how to assess ...
XRP remains unable to break above $1.30, trading around the mid-$1.1s as traders weigh whether a reclaim $1.30? is wi...
A troubling scam shows how families paid $12K Italy for a soccer camp that vanished. This guide breaks down warning s...
A Seattle federal court is weighing Zillow's bid to dismiss a consolidated RESPA lawsuit accusing the company of stee...
A sudden price glitch on a popular trading app sent bitcoin price crashes near zero for a moment, leaving traders puz...